Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
$1.73
-2.3%
$1.40
$0.86
$3.36
$104.79M0.2357,089 shs373,890 shs
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
$11.35
+5.6%
$9.62
$3.35
$20.24
$318.28M1.29227,218 shs88,610 shs
Immuneering Corporation stock logo
IMRX
Immuneering
$6.05
-7.4%
$5.68
$1.10
$10.08
$251.50M0.473.29 million shs3.50 million shs
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
$40.23
+7.7%
$30.50
$8.13
$41.00
$377.25M0.2464,679 shs58,178 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
0.00%+21.83%+25.36%+48.50%-30.80%
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
0.00%-4.78%+3.28%+185.53%-36.25%
Immuneering Corporation stock logo
IMRX
Immuneering
0.00%-25.12%+10.81%+78.47%+148.97%
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
0.00%+10.77%+32.16%+79.12%+4,022,999,900.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
$1.73
-2.3%
$1.40
$0.86
$3.36
$104.79M0.2357,089 shs373,890 shs
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
$11.35
+5.6%
$9.62
$3.35
$20.24
$318.28M1.29227,218 shs88,610 shs
Immuneering Corporation stock logo
IMRX
Immuneering
$6.05
-7.4%
$5.68
$1.10
$10.08
$251.50M0.473.29 million shs3.50 million shs
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
$40.23
+7.7%
$30.50
$8.13
$41.00
$377.25M0.2464,679 shs58,178 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
0.00%+21.83%+25.36%+48.50%-30.80%
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
0.00%-4.78%+3.28%+185.53%-36.25%
Immuneering Corporation stock logo
IMRX
Immuneering
0.00%-25.12%+10.81%+78.47%+148.97%
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
0.00%+10.77%+32.16%+79.12%+4,022,999,900.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
2.60
Moderate Buy$7.00304.62% Upside
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
3.00
Buy$22.2095.59% Upside
Immuneering Corporation stock logo
IMRX
Immuneering
2.43
Hold$16.40171.07% Upside
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
2.60
Moderate Buy$64.2559.71% Upside

Current Analyst Ratings Breakdown

Latest ABOS, TVRD, IMRX, and CTNM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/30/2025
Immuneering Corporation stock logo
IMRX
Immuneering
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$11.00
9/27/2025
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
9/27/2025
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
9/27/2025
Immuneering Corporation stock logo
IMRX
Immuneering
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
9/27/2025
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E)
9/26/2025
Immuneering Corporation stock logo
IMRX
Immuneering
Chardan Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$13.00 ➝ $20.00
9/25/2025
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
Leerink Partnrs
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
9/25/2025
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$20.00
9/25/2025
Immuneering Corporation stock logo
IMRX
Immuneering
Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$21.00 ➝ $30.00
9/15/2025
Immuneering Corporation stock logo
IMRX
Immuneering
Needham & Company LLC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$8.00 ➝ $11.00
8/26/2025
Immuneering Corporation stock logo
IMRX
Immuneering
Needham & Company LLC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$8.00
(Data available from 10/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
N/AN/AN/AN/A$3.03 per shareN/A
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
$50M6.37N/AN/A$7.66 per share1.48
Immuneering Corporation stock logo
IMRX
Immuneering
$320K785.93N/AN/A$1.33 per share4.55
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
$7.14M52.85N/AN/A($3.02) per share-13.32
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
-$102.33M-$2.28N/AN/AN/AN/A-81.39%-61.96%11/11/2025 (Estimated)
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
-$42.26M-$2.20N/AN/AN/AN/A-29.75%-28.08%11/5/2025 (Estimated)
Immuneering Corporation stock logo
IMRX
Immuneering
-$61.04M-$1.89N/AN/AN/AN/A-146.28%-117.22%11/12/2025 (Estimated)
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
-$70.87MN/A0.00N/A-678.79%-565.83%-66.71%N/A

Latest ABOS, TVRD, IMRX, and CTNM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
-$0.51-$1.00-$0.49-$1.00N/AN/A
8/13/2025Q2 2025
Immuneering Corporation stock logo
IMRX
Immuneering
-$0.40-$0.40N/A-$0.40N/AN/A
8/12/2025Q2 2025
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
-$0.54-$0.68-$0.14-$0.68N/AN/A
8/5/2025Q2 2025
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
-$0.56-$0.62-$0.06-$0.62$7.50 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
N/AN/AN/AN/AN/A
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
N/AN/AN/AN/AN/A
Immuneering Corporation stock logo
IMRX
Immuneering
N/AN/AN/AN/AN/A
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
0.26
5.97
5.97
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
N/A
24.51
24.51
Immuneering Corporation stock logo
IMRX
Immuneering
N/A
3.70
3.70
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
N/A
4.04
4.04

Institutional Ownership

CompanyInstitutional Ownership
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
71.01%
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
N/A
Immuneering Corporation stock logo
IMRX
Immuneering
67.65%
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
44.66%

Insider Ownership

CompanyInsider Ownership
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
9.30%
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
11.30%
Immuneering Corporation stock logo
IMRX
Immuneering
22.90%
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
3.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
2060.57 million54.94 millionOptionable
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
3128.04 million24.87 millionN/A
Immuneering Corporation stock logo
IMRX
Immuneering
6041.57 million32.05 millionNot Optionable
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
809.38 million9.09 millionN/A

Recent News About These Companies

BTIG biotech analyst holds a dinner meeting
Tvardi Therapeutics (TVRD) Receives a Buy from Piper Sandler
Tvardi: Q2 Earnings Snapshot
TVRD Tvardi Therapeutics, Inc.
Tvardi Therapeutics Inc (TVRD)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Acumen Pharmaceuticals stock logo

Acumen Pharmaceuticals NASDAQ:ABOS

$1.73 -0.04 (-2.26%)
Closing price 10/3/2025 04:00 PM Eastern
Extended Trading
$1.77 +0.04 (+2.25%)
As of 10/3/2025 06:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

Contineum Therapeutics stock logo

Contineum Therapeutics NASDAQ:CTNM

$11.35 +0.60 (+5.58%)
Closing price 10/3/2025 04:00 PM Eastern
Extended Trading
$11.08 -0.28 (-2.42%)
As of 10/3/2025 04:26 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.

Immuneering stock logo

Immuneering NASDAQ:IMRX

$6.05 -0.48 (-7.35%)
Closing price 10/3/2025 04:00 PM Eastern
Extended Trading
$6.11 +0.06 (+1.01%)
As of 10/3/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.

Tvardi Therapeutics stock logo

Tvardi Therapeutics NASDAQ:TVRD

$40.23 +2.86 (+7.65%)
As of 10/3/2025 04:00 PM Eastern

Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.